What Concentra Biosciences does

Concentra Biosciences, LLC is a privately held biotech holding and acquisition vehicle headquartered in San Diego, USA, controlled by Kevin Tang through Tang Capital Partners. Rather than developing its own therapeutics, the company systematically acquires struggling or undervalued biotechnology companies and consolidates them as wholly owned subsidiaries, extracting value through discounted entry relative to prior public valuations. Its completed acquisitions include Jounce Therapeutics (May 2023, approximately $97.5 million) and Theseus Pharmaceuticals (February 2024, $185 million), with 2025 announcements covering iTeos Therapeutics, CARGO Therapeutics, Elevation Oncology, and Kronos Bio.

The company's business model is deal-driven rather than product-driven: there are no disclosed proprietary products, technologies, or revenue streams, and pricing or revenue figures are not publicly disclosed. Each acquired entity is retained as a separately branded subsidiary focused on its original therapeutic area — immunotherapy, cell therapy, cancer therapeutics, and pharmaceutical development — allowing Concentra to operate a portfolio of clinical-stage assets without bearing the full cost of independent R&D. Deal financing is structured through tender offers and merger agreements, typically combining per-share cash consideration with contingent value rights tied to future milestones.

Concentra's competitive positioning rests on its sponsor backing, deal-sourcing expertise, and willingness to execute distressed biotech buyouts that other acquirers avoid. The company's 2025 transaction cadence — four announced acquisitions within roughly two months — has been characterized externally as a 'serial acquirer' pattern, though its failed bid for Kezar Life Sciences in 2024 (rejected as substantially undervalued and subsequently repriced by Aurinia Pharmaceuticals) demonstrates that the strategy is not without execution risk.

Name

Concentra Biosciences

Legal name

Concentra Biosciences, LLC

Website

https://concentrabiosciences.com

Company type

Private

Operating status

Operating

Short description

Concentra Biosciences is a privately held biotech holding and acquisition vehicle controlled by Kevin Tang through Tang Capital Partners, which acquires and consolidates struggling biotech companies as wholly owned subsidiaries. It has completed or announced multiple distressed-asset buyouts since 2023, spanning immunotherapy, cell therapy, and oncology.

Ownership category

akta.pro rank

Product category

Biotech Holding Company

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB)

akta.pro secondary industry

Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)

Keywords

• Biotech acquisitions
• Specialty pharma holding
• Distressed biotech buyouts
• Oncology pipeline consolidation
• Biotech investment vehicle

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Operations, Technology or R&D, Personnel, Others

Core offering

Concentra Biosciences is a privately-held biotech investment and acquisition vehicle that acquires and consolidates struggling or undervalued biotechnology companies. Rather than developing its own drug pipeline, the company deploys capital through tender offers and merger agreements to take struggling biotechs private as wholly owned subsidiaries, providing liquidity to shareholders and consolidating therapeutic pipeline assets.

Product overview

Concentra Biosciences, LLC is a biotechnology investment and holding company that acquires and consolidates struggling biotech companies. Rather than developing its own products, the company pursues acquisition strategies, having acquired Jounce Therapeutics (May 2023), Theseus Pharmaceuticals (February 2024), and holding agreements to acquire iTeos Therapeutics, CARGO Therapeutics, and Elevation Oncology in 2025. The company does not appear to offer a distinct consumer or enterprise product; its business model centers on acquiring biotech firms and integrating them as wholly owned subsidiaries.

Differentiator

Problem solved

Functional benefit

Products and services

• Jounce Therapeutics (wholly owned subsidiary)
• Theseus Pharmaceuticals (wholly owned subsidiary)
• iTeos Therapeutics (wholly owned subsidiary)
• CARGO Therapeutics (wholly owned subsidiary) Cell therapy and oncology subsidiary agreed to be acquired for approximately $4.379 per share plus contingent rights, with tender offer expected to complete August 2025.
• Elevation Oncology (wholly owned subsidiary) Oncology therapeutics subsidiary entered merger agreement to be acquired for $0.36 per share plus a contingent value right, with transaction expected to close July 2025 subject to $26.4 million available cash condition.

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Six partnerships are on record, tiered minor and core.

• Kezar Life SciencesminorStrategic or Co-development Partner · 30 March 2026Concentra Biosciences (through Kevin Tang) previously attempted and failed to acquire Kezar Life Sciences in 2024. Kezar rejected Concentra's bid of $1.10 per share plus CVR as substantially undervalued. Kezar adopted poison pill rights plan. Deal subsequently repriced by Aurinia Pharmaceuticals.
• iTeos TherapeuticscoreStrategic or Co-development Partner · 21 July 2025iTeos Therapeutics entered into definitive merger agreement to be acquired by Concentra Biosciences for approximately $10.047 per share in cash plus contingent value right. Tender offer expected to commence by August 1, 2025, expected to close Q3 2025.
• CARGO TherapeuticscoreStrategic or Co-development Partner · 8 July 2025CARGO Therapeutics agreed to be acquired by Concentra Biosciences for $4.379 per share plus contingent rights. Acquisition involves tender offer expected to complete August 2025, subject to closing conditions.
• Elevation OncologycoreStrategic or Co-development Partner · 9 June 2025Elevation Oncology entered into merger agreement with Concentra Biosciences to be acquired for $0.36 per share plus contingent value right. Transaction expected to close July 2025 with stockholder tender and $26.4 million available cash conditions.
• Theseus PharmaceuticalscoreStrategic or Co-development Partner · 1 February 2024Concentra Biosciences completed acquisition of Theseus Pharmaceuticals after offer process began November 2023, closing February 2024. Deal valued at $185 million with cash per share between $3.90-$4.05 plus contingent value rights.
• Jounce TherapeuticscoreStrategic or Co-development Partner · 1 May 2023Concentra Biosciences completed acquisition of Jounce Therapeutics for approximately $97.5 million through tender offer and merger. Jounce became a wholly owned subsidiary of Concentra with transaction finalized early May 2023.

Scale indicators3 records

Recent moves6 records

Expansion highlights3 records

Others

• RA Capital Management: RA Capital is a healthcare-focused crossover investor spanning public and private biotech. It frequently invests in the same small/mid-cap clinical-stage companies that Concentra targets for acquisition.
• OrbiMed Advisors: OrbiMed Advisors is a healthcare-dedicated investment firm spanning venture, growth, and public-equity strategies, with deep involvement in biotech platforms and therapeutic programs relevant to Concentra's M&A targets.
• Baker Bros. Advisors: Baker Bros. Advisors is a long-only biotech-focused investment firm with deep public and private life sciences positions. It operates as a financial peer in the same small/mid-cap biotech universe that Concentra pursues.
• Deerfield Management: Deerfield Management is a healthcare-focused investment firm providing capital and operational support to biopharma across the lifecycle. It is a thematic peer active across the biotech capital stack.
• Perceptive Advisors: Perceptive Advisors is a healthcare-focused investment manager with significant biotech equity and credit exposure. It is an active financial peer in the distressed biotech acquisition space.
• EcoR1 Capital: EcoR1 Capital is a biotech-focused fund that takes active positions in public and private life sciences companies and frequently engages with management on strategic alternatives—overlapping with Concentra's sourcing universe.
• BVF Partners: BVF Partners is a biotech-focused investment manager known for concentrated, often activist positions in life sciences equities, including struggling biotechs. It is a frequent financial peer competing for the same distressed assets Concentra targets.

Broad incumbents

• BridgeBio Pharma: BridgeBio develops and commercializes therapeutics through a hub-and-spoke subsidiary model. While it in-licenses rather than buys distressed biotechs outright, it shares Concentra's multi-asset biotech platform structure and pipeline-consolidation ethos.
• Royalty Pharma: Royalty Pharma acquires biopharmaceutical royalty streams and similar economic interests in drugs at scale. While its instruments are financial rather than operating equity, it is a broad incumbent pursuing a similar capital-deployment model in the same biotech asset universe.

Direct peers

• Roivant Sciences: Roivant Sciences acquires and develops therapeutic assets through subsidiary 'Vants'—a holding-style model that is the closest operating analog to Concentra's serial-acquirer approach in biotech. Both aggregate pipeline assets under a single corporate umbrella.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A6 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Concentra Biosciences